SMYD2 Antibody (F-9): sc-393827

SMYD2 Antibody (F-9) is a mouse monoclonal IgG1 kappa light chain antibody that detects SMYD2 protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). SMYD2 (F-9) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. SMYD2, also known as SET and MYND domain containing 2, KMT3C, HSKM-B, or ZMYND14, is a 433 amino acid protein characterized by the presence of one SET domain and one MYND-type zinc finger. SMYD2 is predominantly expressed in the liver, heart, kidney, ovary, and brain, where SMYD2 functions as a lysine methyltransferase. SMYD2 methylation activity on p53 tumor suppressor protein is particularly significant, as SMYD2 may play a crucial role in regulating p53-mediated transcriptional repression, which is vital for maintaining cellular homeostasis and preventing tumorigenesis. SMYD2 gene is located on human chromosome 1, a region that spans 260 million base pairs and contains over 3,000 genes, many of which are associated with various diseases, including familial adenomatous polyposis and several neurodegenerative disorders. Chromosome 1 is implicated in numerous cancers, such as head and neck cancer, malignant melanoma, and multiple myeloma, highlighting the importance of studying SMYD2 in cancer biology and therapeutic development.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

SMYD2 Antibody (F-9) References:

1. Identification and characterization of Smyd2: a split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex.  |  Brown, MA., et al. 2006. Mol Cancer. 5: 26. PMID: 16805913
2. Repression of p53 activity by Smyd2-mediated methylation.  |  Huang, J., et al. 2006. Nature. 444: 629-32. PMID: 17108971
3. The tale of two domains: proteomics and genomics analysis of SMYD2, a new histone methyltransferase.  |  Abu-Farha, M., et al. 2008. Mol Cell Proteomics. 7: 560-72. PMID: 18065756
4. Protein methylation: a new mechanism of p53 tumor suppressor regulation.  |  Scoumanne, A. and Chen, X. 2008. Histol Histopathol. 23: 1143-9. PMID: 18581285
5. Tumor slices as a model to evaluate doxorubicin in vitro treatment and expression of trios of genes PRSS11, MTSS1, CLPTM1 and PRSS11, MTSS1, SMYD2 in canine mammary gland cancer.  |  Sobral, RA., et al. 2008. Acta Vet Scand. 50: 27. PMID: 18601734
6. smyd1 and smyd2 are expressed in muscle tissue in Xenopus laevis.  |  Kawamura, S., et al. 2008. Cytotechnology. 57: 161-8. PMID: 19003161
7. Mapping and expression analyses during porcine foetal muscle development of 12 genes involved in histone modifications.  |  Peng, YB., et al. 2009. Anim Genet. 40: 242-6. PMID: 19133938
8. Targeting SMYD2 inhibits prostate cancer cell growth by regulating c-Myc signaling.  |  Li, J., et al. 2023. Mol Carcinog. 62: 940-950. PMID: 37036190
9. SMYD2 inhibition-mediated hypomethylation of Ku70 contributes to impaired nonhomologous end joining repair and antitumor immunity.  |  Tang, M., et al. 2023. Sci Adv. 9: eade6624. PMID: 37315132
10. Cytoskeleton remodeling induced by SMYD2 methyltransferase drives breast cancer metastasis.  |  Casanova, AG., et al. 2024. Cell Discov. 10: 12. PMID: 38296970
11. The lysine methyltransferase SMYD2 facilitates neointimal hyperplasia by regulating the HDAC3-SRF axis.  |  Zhong, X., et al. 2024. Acta Pharm Sin B. 14: 712-728. PMID: 38322347
12. SMYD2-Methylated PPARγ Facilitates Hypoxia-Induced Pulmonary Hypertension by Activating Mitophagy.  |  Li, Y., et al. 2024. Circ Res. 135: 93-109. PMID: 38770649

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-SMYD2 Antibody (F-9) has 4 citations in a variety of scientific publications.

Primary antibodies like Anti-SMYD2 Antibody (F-9) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

SMYD2 Antibody (F-9) Specifications

Alternate Product Name: SMYD2

Product Clone Name: F-9

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 182-433

Epitope Target: SMYD2

Epitope Species: human

Product Reactivity/Detection: SMYD2

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 4 citations in various scientific publications

Available Conjugates/Forms for SMYD2 Antibody (F-9): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin